Management of multidrug-resistant tuberculosis in Italy

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 5, 2005, Pages 507-513

  Ferrara, G ^a   Richeldi, L ^a   Bugiani, M ^b   Cirillo, D ^c   Besozzi, G ^d   Nutini, S ^e   Casali, L ^f   Fiorentini, F ^g   Codecasa, L R ^h   Migliori, Giovanni B ⁱ  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Pneumology Department   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d Azienda Ospedaliera E Morelli   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f University of Terni   (Italy)

^g Pneumology Department   (Italy)

^h OSPEDALE NIGUARDA CA GRANDA   (Italy)

ⁱ IRCCS   (Italy)

Author keywords

Italy; Management; MDR; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ADULT; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRATION; INFECTION RISK; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; OUTCOMES RESEARCH; PATIENT REFERRAL; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SUPERINFECTION; TREATMENT OUTCOME; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ADULT; EMIGRATION AND IMMIGRATION; FEMALE; HUMANS; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 20844456610     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Espinal M A, Laszlo A, Simonsen L, et al. Global trends in resistance to anti-tuberculosis drugs. World Health Organization/International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 2001; 344: 1294-1303.
2. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
3. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
4. Narita M, Alonso P, Lauzardo M, Rollender E S, Pitchenik A E, Ashkin D. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997. Chest 2001; 120: 343-348.
5. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
6. Migliori G B, Fattorini L, Vaccarino P, et al. Prevalence of resistance to anti-tuberculosis drugs: results of the 1998/99 national survey in Italy. Int J Tuberc Lung Dis 2002; 6: 32-38.
7. Pablos-Mendez A, Raviglione M C, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization- International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998; 338: 1641-1649.
8. Migliori G B, Ambrosetti M, Fattorini L, et al. Surveillance of anti-tuberculosis drug resistance: results of the 1998/1999 proficiency testing in Italy. SMIRA (Italian Multicentre Study on Antituberculosis Drug Resistance) Study Group. Int J Tuberc Lung Dis 2000; 4: 940-946.
9. Centis R, Ianni A, Migliori G B. Evaluation of tuberculosis treatment results in Italy, report 1998. Tuberculosis section of the National AIPO Study Group on Infectious Disease and the SMIRA Group. Monaldi Arch Chest Dis 2000; 55: 293-298.
10. Rieder H L, Zellweger J P, Raviglione M C, Keizer S T, Migliori G B. Tuberculosis control in Europe and international migration. Eur Respir J 1994; 7: 1545-1553.
11. Rieder H L, Watson J M, Raviglione M C, et al. Surveillance of tuberculosis in Europe. Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting on tuberculosis cases. Eur Respir J 1996; 9: 1097-1104.
12. Veen J, Raviglione M, Rieder H L, et al. Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J 1998; 12: 505-510.
13. Broekmans J F, Migliori G B, Rieder H L, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19: 765-775.
14. Aziz A M, Laszlo A, Raviglione M, Rieder H L, Espinal M, Wright A. Guidelines for surveillance of drug resistance in tuberculosis. Geneva, Switzerland: WHO, 2003.
15. Crofton J. Guidelines for the management of drug resistant tuberculosis. Geneva, Switzerland: WHO, 1997.
16. Maher D C P, Spinaci S, Harries A. Treatment of tuberculosis: guidelines for national programmes. Geneva, Switzerland: WHO, 1997.
17. Stata Corporation. Stata Statistical Software: Release 7.0. ed. College Station, TX: Stata Corp, 2001.
18. Farmer P, Bayona J, Becerra M, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 1998; 2: 869-876.
19. White V L, Moore-Gillon J. Resource implications of patients with multidrug resistant tuberculosis. Thorax 2000; 55: 962-963.
20. Suarez P G, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989.
21. Trivedi S S, Desai S G. Primaty anti-tuberculosis drug resistance and acquired rifampicin resistance in Gujarat, India. Tubercle 1988; 69: 37-42.
22. Gilad J, Borer A, Riesenberg K, Peled N, Sci M, Schlaeffer F. Epidemiology and ethnic distribution of multidrug-resistant tuberculosis in Shoutern Israel, 1992-1997. Chest 2000; 117: 738-743.
23. Geng E, Kreiswirth B, Driver C, et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 2002; 346: 1453-1458.
24. Havlir D V, Barnes P F. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340: 367-373.
25. Moro M L, Errante I, Infuso A, et al. Effectiveness of infection control measures in controlling a nosocomial outbreak of multidrug-resistant tuberculosis among HIV patients in Italy. Int J Tuberc Lung Dis 2000; 4: 61-68.
26. Bashar M, Alcabes P, Rom W N, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest 2001; 120: 1514-1519.
27. Kritski A L, Rodrigues de Jesus L S, Andrade M K, et al. Re-treatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest 1997; 111: 1162-1167.
28. Pablos-Mendez A, Blustein J, Knirsch C A. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997; 87: 574-549.
29. Repubblica Italiana, art 115, 1, b, DL 112, 31/03/98. Gazzetta Ufficiale, 1999. 40 (18/02/99).
30. Espinal M A, Kim S J, Suarez P G, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in six countries. JAMA 2000; 283: 2537-2545.
31. Medical Research Council Streptomycin in Tuberculosis Trial Committee. Streptomycin treatment for pulmonary tuberculosis. BMJ 1948; ii: 169-782.
32. Mukherjee J S, Rich M L, Socci A R, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-481.
33. Migliori G B, Espinal M, Danilova I D, Punga V V, Grzemska M, Raviglione M C. Frequency of recurrence among MDR-TB cases 'successfully' treated with standardised short-course chemotherapy. Int J Tuberc Lung Dis 2002; 6: 858-864.
34. Furin J J, Mitnick C D, Shin S S, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655.